These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16892911)

  • 1. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T; Gilbert PB; Self SG
    J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
    Gilbert PB; McKeague IW; Sun Y
    Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
    Mehrotra DV; Li X; Gilbert PB
    Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
    Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
    J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reformulating the hazard ratio to enhance communication with clinical investigators.
    Moser BK; McCann MH
    Clin Trials; 2008; 5(3):248-52. PubMed ID: 18559414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
    Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):577-85. PubMed ID: 8548338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
    Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW
    J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
    Li Z; Gilbert P; Nan B
    Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating incidence of HIV infection in childbearing age African women using serial prevalence data from antenatal clinics.
    Sakarovitch C; Alioum A; Ekouevi DK; Msellati P; Leroy V; Dabis F
    Stat Med; 2007 Jan; 26(2):320-35. PubMed ID: 16625518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV vaccine efficacy trials: A brief history, and options for going forward.
    McKinnon LR; Card CM;
    AIDS Rev; 2010; 12(4):209-17. PubMed ID: 21179185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
    Flynn NM; Forthal DN; Harro CD; Judson FN; Mayer KH; Para MF;
    J Infect Dis; 2005 Mar; 191(5):654-65. PubMed ID: 15688278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First AIDS vaccine tested did not protect, but gives scientific leads.
    James JS
    AIDS Treat News; 2003 Mar; (389):6. PubMed ID: 12712937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.